Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Clinical Videos

Quadricuspid Aortic Valve in a Neonate With Fallot’s Tetralogy

Andriana Anagnostopoulou, MSc, MRCPCH1,2; Nikolaos Andreou, MD2; Tania Siahanidou, PHD3

02/22/2024
Video. The valve consisted of 3 equal cusps and a smaller one, which is type B in the Hurwitz and Roberts classification.

 

Video Supplement to "Quadricuspid Aortic Valve in a Neonate With Fallot’s Tetralogy" (Clinical Image).


Related Content

Clinical Images
Role of Diastology in Transcatheter Aortic Valve Implantation
02/24/2018

Sivasankaran Sivasubramonian, DM;  Arun Gopalakrishnan, DM;  Bijulal Sasidharan, DM;  Ajitkumar Valaparambil, DM

Sivasankaran Sivasubramonian, DM;  Ar...
Transient elevation of LV diastolic pressure above LA pressure can occur in severe aortic regurgitation in the diastasis phase. Mitral E wave reversal in such a situation could serve as non-invasive evidence of elevated left ventricular...
Transient elevation of LV diastolic pressure above LA pressure can occur in severe aortic regurgitation in the diastasis phase. Mitral E wave reversal in such a situation could serve as non-invasive evidence of elevated left ventricular...
Transient elevation of LV...
02/24/2018
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

News

Pulmonary Hypertension
Hormone Replacement Therapy (HRT) May Improve Pulmonary Hypertension and Right Ventricular Function
05/20/2024

American Thoracic Society News

American Thoracic Society News ...
The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...
The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...
The results: Across all...
05/20/2024
Cath Lab Digest
Transcatheter Heart Valves
LANDMARK Trial: Meril Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT
05/17/2024

Meril Life Sciences News

Meril Life Sciences News
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman &...
05/17/2024
Cath Lab Digest
Heart Failure
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
05/17/2024

Implicity News

Implicity News
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the...
05/17/2024
Cath Lab Digest
Coronary Implants
DESyne BDS Plus RCT: Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
05/16/2024

Elixir Medical News

Elixir Medical News
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
Primary Outcomes From PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact IVL in Moderate to Severe Calcified Coronary Artery Lesions
05/16/2024

Elixir Medical News

Elixir Medical News
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact...
05/16/2024
Cath Lab Digest
Bioadaptors
BIOADAPTOR RCT Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
05/16/2024

Elixir Medical News

Elixir Medical News
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
FastWave Medical Granted Fifth Utility Patent Reflecting Continuous Expansion of IVL IP Portfolio
05/16/2024

FastWave Medical News

FastWave Medical News
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent...
05/16/2024
Cath Lab Digest
IMAGING
One in Three People Die Due to Atherosclerosis: A New Initiative, REACT, Aims to Find New Ways to Prevent It
05/16/2024

Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) News

Centro Nacional de Investigaciones Ca...
“REACT will develop – at scale - methods to directly visualize the disease (atherosclerosis),” says Dr. Borja Ibáñez, Scientific Director of CNIC, cardiologist at Fundación Jiménez Díaz hospital, and leader of the Spanish part of the study.
“REACT will develop – at scale - methods to directly visualize the disease (atherosclerosis),” says Dr. Borja Ibáñez, Scientific Director of CNIC, cardiologist at Fundación Jiménez Díaz hospital, and leader of the Spanish part of the study.
“REACT will develop – at scale -...
05/16/2024
Cath Lab Digest
hypertension
Patient “Chronotype” Could Impact Best Time to Take Blood Pressure Medication
05/16/2024

University of Dundee News

University of Dundee News
Scientists observed that so-called “morning larks” (earlier chronotypes) who took their prescribed blood pressure medication in the morning were less likely to experience a heart attack than those who were “misaligned” and took it in the...
Scientists observed that so-called “morning larks” (earlier chronotypes) who took their prescribed blood pressure medication in the morning were less likely to experience a heart attack than those who were “misaligned” and took it in the...
Scientists observed that...
05/16/2024
Cath Lab Digest
Extreme exercise
JAMA: Exercise Does Not Accelerate Artery Plaque Buildup More Often Seen in Fitness Enthusiasts
05/16/2024

UT Southwestern Medical Center News

UT Southwestern Medical Center News ...
The study, which analyzed more than 8,700 participants from 1998-2019, provides important insight on whether people whose heart scans detect higher calcium should modify their exercise regimen to slow the plaque buildup in arteries.
The study, which analyzed more than 8,700 participants from 1998-2019, provides important insight on whether people whose heart scans detect higher calcium should modify their exercise regimen to slow the plaque buildup in arteries.
The study, which analyzed more...
05/16/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Clinical Images
Transcatheter Aortic Valve Replacement in a Patient With Pre-existing Left Ventricular Pseudoaneurysm: The Importance of Pre- and Intra-procedural Imaging
05/20/2024

Avionam Shiran, MD; Alexander Fuks, MD; Keren Zissman, MD; Ronen Jaffe, MD

Avionam Shiran, MD; Alexander Fuks, M...
An 85-year-old man with a history of myocardial infarction and coronary bypass surgery presented with severe symptomatic aortic stenosis.
An 85-year-old man with a history of myocardial infarction and coronary bypass surgery presented with severe symptomatic aortic stenosis.
An 85-year-old man with a...
05/20/2024
Journal of Invasive Cardiology
Rivero-Santana Figure
Clinical Videos
Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification
05/20/2024

Borja Rivero-Santana, MD; Guillermo Galeote, MD, PhD; Alfonso Jurado-Roman, MD, PhD; Santiago Jiménez-Valero, MD, PhD; Ariana Gonzálvez-García MD; Raul Moreno, MD, PhD

Borja Rivero-Santana, MD; Guillermo G...
Video Supplement to "Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification" (Clinical Image).
Video Supplement to "Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification" (Clinical Image).
Video Supplement to "Successful...
05/20/2024
Journal of Invasive Cardiology
Clinical Images
Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification
05/20/2024

Borja Rivero-Santana, MD1,2; Guillermo Galeote, MD, PhD1; Alfonso Jurado-Roman, MD, PhD1,2; Santiago Jiménez-Valero, MD, PhD1,2; Ariana Gonzálvez-García MD1; Raul Moreno, MD, PhD1,2

Borja Rivero-Santana, MD1,2; Guillerm...
An 87-year-old man with a history of heart failure and a modified bio-Bentall Mitroflow 23-mm bioprosthesis (Sorin) was referred to our institution for critical aortic stenosis, which was confirmed by transesophageal echocardiography.
An 87-year-old man with a history of heart failure and a modified bio-Bentall Mitroflow 23-mm bioprosthesis (Sorin) was referred to our institution for critical aortic stenosis, which was confirmed by transesophageal echocardiography.
An 87-year-old man with a...
05/20/2024
Journal of Invasive Cardiology
Pulmonary Hypertension
Hormone Replacement Therapy (HRT) May Improve Pulmonary Hypertension and Right Ventricular Function
05/20/2024

American Thoracic Society News

American Thoracic Society News ...
The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...
The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...
The results: Across all...
05/20/2024
Cath Lab Digest
Transcatheter Heart Valves
LANDMARK Trial: Meril Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT
05/17/2024

Meril Life Sciences News

Meril Life Sciences News
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman &...
05/17/2024
Cath Lab Digest
Heart Failure
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
05/17/2024

Implicity News

Implicity News
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the...
05/17/2024
Cath Lab Digest
Coronary Implants
DESyne BDS Plus RCT: Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
05/16/2024

Elixir Medical News

Elixir Medical News
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
Primary Outcomes From PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact IVL in Moderate to Severe Calcified Coronary Artery Lesions
05/16/2024

Elixir Medical News

Elixir Medical News
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact...
05/16/2024
Cath Lab Digest
Bioadaptors
BIOADAPTOR RCT Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
05/16/2024

Elixir Medical News

Elixir Medical News
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
FastWave Medical Granted Fifth Utility Patent Reflecting Continuous Expansion of IVL IP Portfolio
05/16/2024

FastWave Medical News

FastWave Medical News
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent bolsters the innovative design of FastWave's next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease.
The newly granted patent...
05/16/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement